When do the LORATADINE REDIDOSE patents expire, and when will LORATADINE REDIDOSE go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Ltd	LORATADINE REDIDOSE	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	077153-001	Apr 11, 2007		OTC	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 3, 2026

Loratadine RediDose is an orally disintegrating, nonprescription loratadine product used for temporary relief of allergic rhinitis and urticaria symptoms. Its commercial position is shaped by three factors: the long-expired loratadine patent estate, intense private-label competition, and limited public disclosure of product-level sales. The product has low regulatory barriers but weak differentiation unless its dosage form earns distribution advantages in retail, club, convenience, or e-commerce channels.

What is Loratadine RediDose?

Loratadine RediDose is a 10-mg orally disintegrating tablet containing loratadine, a second-generation antihistamine. The dosage form is designed to dissolve in the mouth without water, although labeling generally directs patients to remove the tablet from the blister immediately before use and place it on the tongue.

Loratadine is indicated for temporary relief of:

Sneezing
Runny nose
Itchy nose or throat
Itchy, watery eyes
Symptoms associated with hay fever and other upper-respiratory allergies
Hives and itching associated with chronic urticaria

The product belongs to the same therapeutic category as Claritin RediTabs, generic loratadine orally disintegrating tablets, cetirizine products such as Zyrtec, and fexofenadine products such as Allegra.

What is the FDA regulatory status of Loratadine RediDose?

Loratadine products are generally marketed in the United States under the FDA’s nonprescription antihistamine framework. Depending on the specific manufacturer, a product may be marketed under an approved abbreviated new drug application, an OTC monograph pathway, or a legacy OTC product framework.

The relevant FDA regulatory characteristics are:

Regulatory item	Status
Active ingredient	Loratadine
Primary use	OTC allergy and hives relief
Common strength	10 mg
Dosage form	Orally disintegrating tablet
Prescription status	Nonprescription
Pediatric use	Label-dependent; many products are labeled for adults and children age 6 and older
FDA exclusivity	No meaningful current market exclusivity
Approval barrier	Low relative to prescription products
Substitution risk	High

The FDA’s OTC monograph system permits competing products to follow established conditions for active ingredients, dosage forms, labeling, and indications. The FDA moved many OTC monograph processes into the administrative-order framework under the CARES Act, but the commercial impact for loratadine is limited because the ingredient has been marketed broadly for decades.[1]

When does Loratadine lose patent exclusivity?

Loratadine lost meaningful U.S. patent exclusivity years ago. The principal loratadine composition patent, U.S. Patent No. 4,282,233, was filed in the late 1970s and issued in 1981. Its ordinary patent term expired long before the current OTC market developed.[2]

The key commercial dates are:

Event	Approximate timing
Loratadine patent issuance	1981
Original prescription launch of Claritin	1990s
FDA approval of prescription Claritin	1993
FDA approval of OTC Claritin	2002
Broad generic and private-label expansion	2000s
Current market	Fully mature, multisource OTC category

Specific orally disintegrating formulations may once have been covered by separate formulation, manufacturing, or packaging patents. Those rights do not create a material barrier today because the product category has been commercialized by numerous manufacturers and retailers.

What patents protect Loratadine RediDose?

No active patent is likely to provide commercially meaningful exclusivity for the basic Loratadine RediDose product. The relevant historical patent categories include:

Active-ingredient patents

The original loratadine compound patent protected the active pharmaceutical ingredient and related chemical subject matter. Those rights expired decades ago.

Method-of-use patents

Loratadine’s principal uses, including allergic rhinitis and urticaria treatment, are established OTC indications. Method-of-use patents do not provide a practical barrier to standard-label generic or private-label products.

Formulation patents

Orally disintegrating tablets can involve patents covering:

Rapid disintegration
Taste masking
Tablet excipients
Compression processes
Blister packaging
Moisture protection
Unit-dose delivery

The commercial value of these rights depends on claim scope and enforceability. A formulation patent covering a particular excipient combination would not necessarily block a competing product using a different disintegration technology.

Packaging and trade dress

Packaging, tablet appearance, and brand presentation may create limited consumer-recognition advantages. They are not substitutes for pharmaceutical exclusivity. Retailers can source competing products with equivalent labeling and dosage-form claims.

What is the Orange Book status of Loratadine RediDose?

The Orange Book is relevant primarily to prescription drug approvals and patent listings. A standard OTC loratadine product does not obtain market protection merely because loratadine products or historical Claritin products appear in FDA approval databases.

For a specific Loratadine RediDose product, the decisive questions are:

Whether the product is associated with an approved NDA or ANDA.
Whether FDA lists any patents for that approval.
Whether the listed product remains marketed.
Whether the relevant patents have expired.
Whether the product is marketed under an OTC monograph rather than a traditional application.

The commercial conclusion is straightforward: loratadine’s active ingredient and principal indications are off-patent, and the market has no current Orange Book barrier comparable to a protected prescription product.

Are there Paragraph IV challenges involving Loratadine RediDose?

Paragraph IV litigation is not a major current risk for Loratadine RediDose. Paragraph IV certifications matter when an ANDA applicant challenges unexpired patents listed for a reference listed drug. Loratadine’s basic product and therapeutic indications are long off-patent, so new ANDA applicants generally face limited patent exposure.

Historical generic competition involved challenges to residual Claritin patents, formulation rights, and related products. Those disputes did not preserve durable market exclusivity for loratadine as an ingredient.

The main present-day risks are commercial rather than patent-based:

Retailer delisting
Contract loss
Price compression
Private-label substitution
Manufacturing disruption
Product recalls
Blister-packaging defects
Failure to meet OTC labeling or quality requirements

How strong is the patent estate for Loratadine RediDose?

The patent estate is weak from a current market-defense perspective.

Patent factor	Assessment
Active ingredient	Expired
Core indications	Mature OTC uses
Basic tablet formulation	Easily substituted
Orally disintegrating format	Potentially differentiated, but generally not exclusive
Packaging	Limited defensive value
Manufacturing process	Possible narrow claims, low category-wide blocking power
Orange Book leverage	Limited
Generic entry risk	High
Private-label risk	Very high

A manufacturer may own technical know-how that is difficult to replicate quickly, particularly around taste masking, tablet hardness, moisture stability, and blister packaging. That know-how can improve supply reliability and product quality but normally does not produce prescription-style pricing power.

What companies compete with Loratadine RediDose?

Competition comes from branded, generic, and retailer-controlled products.

Branded competitors

Claritin RediTabs and related loratadine products
Zyrtec and cetirizine products
Allegra and fexofenadine products
Store-brand versions of each category

Generic and private-label manufacturers

The U.S. market includes products from large OTC suppliers, contract manufacturers, and retail pharmacy suppliers. The same product may be sold under multiple retailer labels while being produced at a common manufacturing site.

Large distribution channels include:

National pharmacies
Mass merchants
Grocery chains
Club stores
Online marketplaces
Health and beauty retailers
Institutional and convenience channels

Retailer private labels exert the strongest pricing pressure because loratadine is a familiar ingredient with low consumer switching costs.

What drives the market for Loratadine RediDose?

Demand is seasonal but recurring. Sales generally rise during spring and early summer allergy periods, with additional demand in late summer and fall depending on regional pollen exposure.

Key market drivers include:

Seasonal allergic rhinitis
Consumer preference for non-drowsy antihistamines
Convenience of water-free dosing
Growth in self-care and OTC medicine use
Retailer demand for low-cost store brands
E-commerce search behavior
Physician and pharmacist familiarity with loratadine
Household stocking of allergy medicines

The RediDose format has a narrower target than standard tablets because many consumers prioritize price over water-free administration. Its strongest use cases are travel, workplace, school, outdoor activity, and consumers who have difficulty swallowing conventional tablets.

What is the financial trajectory of Loratadine RediDose?

Public companies generally do not disclose revenue for an individual generic or private-label loratadine SKU. Financial performance must therefore be evaluated through category economics rather than product-level reported sales.

The expected trajectory is:

Commercial phase	Financial profile
Launch or retailer onboarding	Volume depends on shelf placement, promotional support, and contract pricing
Early expansion	Unit growth can be strong if the product wins private-label or chain distribution
Mature distribution	Revenue becomes stable but pricing declines
Late lifecycle	Margin pressure increases as additional suppliers enter
Displacement or delisting	Revenue can fall rapidly despite continued category demand

Revenue is likely driven more by distribution contracts and seasonal volume than by brand equity. A manufacturer with an exclusive retailer agreement can generate meaningful unit sales without achieving premium pricing. Conversely, a branded product without strong shelf placement can lose volume to a lower-priced store brand.

Financial exposure by business model

Business model	Revenue potential	Margin profile	Primary risk
National brand	Moderate to high	Higher gross margin, higher marketing costs	Brand substitution
Retail private label	High volume potential	Lower unit margin	Contract repricing
Generic pharmacy product	Moderate	Thin margin	Pharmacy and wholesaler competition
Contract manufacturing	Volume-based	Predictable but limited margin	Customer concentration
E-commerce niche brand	Lower volume	Variable margin	Advertising and platform costs

Loratadine RediDose is unlikely to support premium pricing solely on the basis of its active ingredient. Any price premium must come from the dosage form, packaging, brand, product availability, or retailer positioning.

What generic launch scenarios exist for Loratadine RediDose?

Because the active ingredient is off-patent, additional generic or private-label launches can occur with limited litigation exposure.

Scenario 1: Stable mature market

The product retains distribution through a retailer or pharmacy network. Revenue remains seasonal, while average selling price gradually declines.

Scenario 2: Private-label substitution

A retailer replaces the product with a lower-cost equivalent from another supplier. Unit volume may migrate to the replacement product, but the original manufacturer loses revenue quickly.

Scenario 3: Dosage-form premium

The manufacturer preserves pricing through a differentiated blister, taste profile, smaller package, or better disintegration performance. This strategy can protect share but does not create durable exclusivity.

Scenario 4: Manufacturing disruption

A shortage, recall, packaging failure, or supplier interruption can reduce sales during the high-value allergy season. The category’s multisource structure allows retailers to switch suppliers quickly.

Scenario 5: Brand erosion

Consumers migrate from branded loratadine to lower-cost generic or store-brand products. The active ingredient remains in demand, but branded revenue and margin decline.

Does Loratadine RediDose face biosimilar risk?

No. Biosimilar risk does not apply because loratadine is a small-molecule chemical drug, not a biologic. The relevant competitive threats are generic substitution, OTC private-label competition, therapeutic substitution with cetirizine or fexofenadine, and retailer sourcing decisions.

What licensing deals affect Loratadine RediDose?

No major current licensing transaction is publicly associated with a generic Loratadine RediDose product as a distinct commercial asset. Historical Claritin commercialization involved Schering-Plough and related commercial arrangements, but those arrangements do not create current exclusivity for generic loratadine products.

Current licensing value would more likely arise from:

Retailer supply agreements
Contract manufacturing arrangements
Distribution rights
Packaging technology licenses
Formulation know-how
Regional commercialization rights

Such agreements are often private and are not reported at the individual-SKU level.

What geographic markets does Loratadine RediDose cover?

The strongest commercial market is the United States, where loratadine is widely recognized and OTC distribution is extensive. Equivalent loratadine orally disintegrating products are also marketed internationally, but brand names, regulatory pathways, labeling, and patent histories differ by country.

Geographic barriers are generally low because:

The active ingredient is widely available.
The dosage form is established.
Regulatory pathways are familiar.
Multiple contract manufacturers can produce comparable tablets.
Local distributors can source equivalent products.

The main geographic constraints are country-specific registration, labeling, packaging, import requirements, quality-system compliance, and retailer access.

Key Takeaways

Loratadine RediDose is a mature OTC orally disintegrating loratadine product.
The active ingredient and core therapeutic uses are long off-patent.
No current patent estate is likely to block standard generic or private-label entry.
Paragraph IV litigation is not a major present risk.
Biosimilar competition is irrelevant because loratadine is a small molecule.
Revenue is driven by seasonal demand, retailer distribution, and contract volume.
Product-level financial results are generally not publicly disclosed.
The main risks are price erosion, private-label substitution, retailer repricing, and supply-chain failure.
The RediDose format can support limited differentiation but is unlikely to provide durable pricing power.
Commercial strength depends more on distribution and manufacturing execution than on intellectual property.

FAQs About Loratadine RediDose

Is Loratadine RediDose the same as Claritin RediTabs?

It contains the same active ingredient, loratadine, and commonly uses the same 10-mg strength. The products may differ in manufacturer, inactive ingredients, tablet performance, packaging, labeling, and brand positioning.

Can a generic manufacturer launch loratadine orally disintegrating tablets?

Yes. Loratadine is off-patent, and the dosage form is established. A manufacturer must comply with applicable FDA requirements for formulation, manufacturing, labeling, quality, and packaging.

Does Loratadine RediDose have a premium over standard loratadine tablets?

It may carry a price premium in some retail channels because of its water-free dosage form. The premium is limited by competition from generic orally disintegrating tablets and other non-drowsy antihistamines.

Which products compete most directly with Loratadine RediDose?

The closest products are Claritin RediTabs and store-brand loratadine orally disintegrating tablets. Cetirizine and fexofenadine products compete therapeutically but contain different active ingredients.

What would most increase the value of a Loratadine RediDose business?

The strongest value drivers would be durable retailer distribution, reliable manufacturing capacity, favorable supply contracts, efficient blister packaging, low defect rates, and a differentiated consumer brand. Patent protection is unlikely to be the primary source of value.

References

U.S. Food and Drug Administration. (2023). Over-the-counter monograph drug products. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
U.S. Patent and Trademark Office. (1981). U.S. Patent No. 4,282,233: Pharmaceutical compositions containing loratadine. https://patents.google.com
U.S. Food and Drug Administration. (2002). Claritin loratadine nonprescription labeling and regulatory materials. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
National Library of Medicine. (2024). DailyMed: Loratadine drug labels. https://dailymed.nlm.nih.gov/dailymed/

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	118
Patent Applications:	4,298
DailyMed Link:	LORATADINE REDIDOSE at DailyMed

AI Deep Research

Questions you can ask:

Summary for LORATADINE REDIDOSE